Skip to main content
SpringerLink
Log in

Management of Diabetic Dyslipidaemia

  • Chapter
Pharmacotherapy of Diabetes: New Developments

  • 1410 Accesses

Keywords: dyslipidaemia, LDL-cholesterol, small dense LDL, HDL-cholesterol, statins, fibrates, ezetimibe, nicotinic acid.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Zimmet PZ, Alberti KGMM. The changing face of macrovascular disease in non-insulin-dependent diabetes mellitus: an epidemic in progress. Lancet. 1997;350(Suppl. 1):1–4.

    Article  Google Scholar 

  2. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia. 2003; 46:733–749.

    Article  PubMed  Google Scholar 

  3. Betteridge DJ. Dyslipidaemia and diabetes Pract Diabetes Int. 2001;18:201–208.

    Google Scholar 

  4. Assman E, Schulte H. The prospective cardiovascular Munster (PROCAM) study: prevalence of hyperlipidaemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J. 1988;116:1713–1724.

    Article  Google Scholar 

  5. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683–689.

    Article  CAS  PubMed  Google Scholar 

  6. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance in type 2 diabetes. Endcr Rev. 2002;23:201–229.

    Article  CAS  Google Scholar 

  7. Despres J-P. Abdominal obesity: the most prevalent cause of the metabolic syndrome and related cardiometabolic risk. Eur Heart J. 2006;8(Suppl. B) B4–B12.

    Article  CAS  Google Scholar 

  8. Kadowaki T, Yamamuchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26: 439–451.

    Article  CAS  PubMed  Google Scholar 

  9. Chirieac DV, Chirieac LR, Corsetti JP, et al. Glucose-stimulated insulin secretion suppresses hepatic triglyceride-rich lipoprotein and apo B production. Am J Physiol Endocrinol Metabol. 2000;279: E1003–E1011.

    CAS  Google Scholar 

  10. Lin MCM, Gordon D, Wetterau JR. Microsomal triglyceride transfer protein (MTP) regulation in HEPG2 cells: insulin negatively regulates MTP gene expression. J Lipid Res. 1995;36:1073–1081.

    CAS  PubMed  Google Scholar 

  11. Ginsberg HN, Illingworth DG. Postprandial dyslipidaemia; an atherogenic disorder common in patients with diabetes mellitus. Am J Cardiol. 2001;88(Suppl 9):9H–15H.

    Article  CAS  PubMed  Google Scholar 

  12. Lee S-J, Moye LA, Campos H, et al. Hypertri-glyceridaemia but not diabetic status is associated with VLDL containing apolipoprotein CIII in patients with coronary heart disease. Atherosclerosis. 2003;167:293–302.

    Article  CAS  PubMed  Google Scholar 

  13. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest. 2000;106:453–458.

    Article  CAS  PubMed  Google Scholar 

  14. Ceriello A, Tabga C, Tonutti L, et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridaemia and hyperglycaemia on endothelial dysfunction and oxidative stress generation. Effects of short and long-term simvastatin therapy. Circulation. 2002;106:1211–1218.

    Article  PubMed  Google Scholar 

  15. Lamarche B, Rashid S, Lewis GF, etal. HDL metabolism in hypertriglyceridaemic states: an overview. Clin Chem Acta.1999;286:145–161.

    Article  CAS  Google Scholar 

  16. Toth PP. Adiponectin and high density lipoprotein: a metabolic association through thick and thin. Eur Heart J. 26:1579–1581.

    Google Scholar 

  17. Tan KC, Cooper MB, Ling KL, et al. Fasting and postprandial determinants for the occurrence of small dense LDL species in non-insulin-dependent diabetic patients with and without hypertriglyceridaemia: the involvement of insulin, insulin precursor species and insulin resistance. Atherosclerosis. 1995;113:273–287.

    Article  CAS  PubMed  Google Scholar 

  18. Rainwater DL. Lipoprotein correlates of LDL particle size. Atherosclerosis. 2000;148:151–158.

    Article  CAS  PubMed  Google Scholar 

  19. Gray RS, Robbins DC, Wang W, et al. Relation of LDL size to insulin resistance syndrome and coronary heart disease in American Indians. Arterioscler Thromb Vasc Biol. 1997;17:2713–2720.

    CAS  PubMed  Google Scholar 

  20. Stamler J, Vaccaro O, Neaton JD, et al for the Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors and 12 year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434–444.

    Article  CAS  PubMed  Google Scholar 

  21. Turner RC, Millns H, Neil HAW for the United Kingdom Prospective Diabetes Study Group. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS:23). BMJ. 1998;316:823–828.

    CAS  PubMed  Google Scholar 

  22. Howard BV, Robbins DC, Sievers ML, et al. LDL cholesterol is a strong predictor of coronary artery disease in diabetic individuals with insulin resistance and low LDL. The Strong Heart Study. Arterioscler Thromb Vasc Biol. 2000;20:830–835.

    CAS  Google Scholar 

  23. Chapman MJ, Guerin M, Bruckert E. Atherogenic dense low density lipoproteins: pathophysiology and new therapeutic approaches. Eur Heart J. 1998;19: (Suppl. A) A24–A30.

    CAS  PubMed  Google Scholar 

  24. Chait A, Wight TN. Interaction of native and modified low density lipoproteins with extracellular matrix. Curr Opin Lipidol. 2000;11:451–456.

    Article  Google Scholar 

  25. Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridaemic hyper apoB: the unappreciated atherogenic dyslipidaemia in type 2 diabetes mellitus. Ann Intern Med. 2001;135:447–459.

    CAS  PubMed  Google Scholar 

  26. Steinbrecher UP, Witztum JL. Glycosylation of low density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism. Diabetes. 1984;33:130–134.

    Article  CAS  PubMed  Google Scholar 

  27. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8–15.

    CAS  PubMed  Google Scholar 

  28. Kreiger M. Scavenger receptor class B type 1 is a multi-ligand HDL receptor that influences diverse physiologic systems. J Clin Invest. 2001;108:793–797.

    Google Scholar 

  29. Schmitz G, Kaminski WE. ATP-binding cassette (ABC) transporter in atherosclerosis. Curr Atheroscler Rep. 2002;4:243–251.

    Article  PubMed  Google Scholar 

  30. JBS 2 Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005;91(Suppl. V):v1–v52.

    Google Scholar 

  31. Yusuf S, Hawken S, Ounpuu S, et al. on behalf of the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): a case control study. Lancet. 2004; 364:937–952.

    Article  PubMed  Google Scholar 

  32. Hulley SB, Rosenman RH, Bawal RD, et al. Epidemiology as a guide to clinical decisions: the association between triglyceride and coronary heart disease. N Engl J Med. 1980;302:1383–1389.

    Article  CAS  PubMed  Google Scholar 

  33. Hokanson E, Austin MA. Plasma triglyceride is a risk factor for cardiovascular disease independent of high density lipoprotein cholesterol level; a meta-analysis of population-based prospective studies. J Cardiovascular Risk. 1996;3:213–219.

    Article  CAS  Google Scholar 

  34. Assmann E, Sculte H. Relation of high density lipoprotein cholesterol and triglycerides to incidence of coronary artery disease (the PROCAM experience). Am J Cardiol. 1992;70:733–737.

    Article  CAS  PubMed  Google Scholar 

  35. Manninen V, Tenkanen H, Koskinen P, et al. Joint effects of triglycerides and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease in the Helsinki Heart Study. Implications for treatment. Circulation. 1992;85:37–45.

    CAS  PubMed  Google Scholar 

  36. Lehto S, Ronnemaa T, Haffner SM, et al. Dyslipidaemia and hyperglycaemia predict coronary heart disease in middle-aged patients with NIDDM. Diabetes. 1997;46:1354–1359.

    Article  CAS  PubMed  Google Scholar 

  37. Betteridge DJ, Morrell JM. Lipids and Coronary Heart Disease. Arnold, London. 2003.

    Google Scholar 

  38. Betteridge DJ, Khan M. Statins and Coronary Artery Disease. (2nd edition) Science Press. London. 2003.

    Google Scholar 

  39. Scandinavian Simvastatin Survival Study Group (4S) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet. 1994;344:1383–1389.

    Google Scholar 

  40. Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614–620.

    Article  CAS  PubMed  Google Scholar 

  41. Betteridge DJ. Benefits of lipid-lowering therapy in patients with type 2 diabetes Am J Med. 2005;118: (suppl 12A) 10S–15S.

    Article  CAS  Google Scholar 

  42. Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-trated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Subgroup analysis in the Scandinavian Simvastatin Survival Study. Arch Int Med. 1999;159:2661–2667.

    Article  CAS  Google Scholar 

  43. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet. 2003;361:2005–2016.

    Article  CAS  Google Scholar 

  44. Athyros VG, Papagrorgious AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Education Program Goal versus “usual”care in secondary coronary heart disease prevention. Curr Med Res Opin. 2002;18:220–228.

    Article  PubMed  Google Scholar 

  45. Cannon CP, Braunwald E, Mccabe CH, et al. Intensive versus moderate lipid-lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350:1495–1504.

    Article  CAS  PubMed  Google Scholar 

  46. LaRosa JC, Grundy SM, Waters D, et al. for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352:1452–1435.

    Article  Google Scholar 

  47. Shepherd J, Barter P, Carmena R. et al. Effect of lowering LDL cholesterol substantially below recommended levels in patients with coronary heart disease: the Treating to New Targets (TNT) Study. Diabetes Care. 2006;29:1220–1226.

    Article  CAS  PubMed  Google Scholar 

  48. Deedwania P, Barter P, Carmena R, et al. Reduction of low density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006;368:919–928.

    Article  CAS  PubMed  Google Scholar 

  49. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. JACC. 2006;48:438–455.

    CAS  PubMed  Google Scholar 

  50. Colhoun HM. Betteridge DJ, Durrington PN, et al. on behalf of the CARDS investigators. Primary prevention of cardiovascular disease in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet. 2004;364:685–696.

    Article  CAS  PubMed  Google Scholar 

  51. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations in the Anglo Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet. 2003;361:1149–1158.

    Article  CAS  PubMed  Google Scholar 

  52. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke and total mortality: an overview of randomized trials. JAMA. 1997;278:313–321.

    Article  CAS  PubMed  Google Scholar 

  53. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischaemic attack. N Engl J Med. 2006;355:549–559.

    Article  Google Scholar 

  54. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088–2093.

    CAS  PubMed  Google Scholar 

  55. Frick MH, Elo O, Haapa K, et al. The Helsinki Heart Study: primary prevention trila with gemfibrozil in middle-aged men with dyslipidaemia. Safety of treatment changes in risk factors and incidence of coronary heart disease. N. Engl J Med. 1987;317: 1237–1245.

    CAS  PubMed  Google Scholar 

  56. Robins SJ, Rubins HB, Collins D, et al. for the Veterans Affairs HDL Intervention Trial (VAHIT). Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N Engl J Med. 1999; 241:410–418.

    Article  Google Scholar 

  57. Bezafibrate Infarction Prevention Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000;102:21–27.

    Google Scholar 

  58. Tenenbaum A, Motro M, Fisman EZ, et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med. 2005;165:1154–1160.

    Article  CAS  PubMed  Google Scholar 

  59. The FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial Lancet. 2005;366:1849–1861.

    Google Scholar 

  60. Colhoun H. After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes? Lancet. 2005;366:1829–1831.

    Article  PubMed  Google Scholar 

  61. Grundy SM, Cleeman JI, Merz CNB, et al. for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227–239.

    Article  PubMed  Google Scholar 

  62. Jones PH, Kafonek S, Laurota I et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolaemia (the CURVES study) Am J Cardio.l 1998;81:582–587.

    Article  CAS  PubMed  Google Scholar 

  63. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial) Am J Cardiol. 2003;92:152–160.

    Article  CAS  PubMed  Google Scholar 

  64. Kashani A, Phillips CO, Foody JM, et al. Statin use is associated with a low incidence of adverse events. Circulation. 2006;114:2788–2797.

    Article  CAS  PubMed  Google Scholar 

  65. Nissen SE, Nicholls Sj, Sipahi I, et al. Effects of very high intensity statin therapy on regression of coronary atherosclerosis. JAMA. 2006;295:1556–1565.

    Article  CAS  PubMed  Google Scholar 

  66. Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick C1-LikeMayo Clin Proc. (NPC1L1) PNAS. 2005;102:8132–8137.

    Article  CAS  PubMed  Google Scholar 

  67. Goldberg AC, Sapre A, Liu J, et al. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolaemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2004;79:620–629.

    Article  CAS  PubMed  Google Scholar 

  68. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 pateints with primary hypercholesterolaemia. A prospective, randomized, double-blind trial. Circulation. 2003;107:2409–2415.

    Article  CAS  PubMed  Google Scholar 

  69. Hunninghake DB. Bile acid sequestering agents (resins) In: Lipoproteins in Health and Disease. Edotors DJ Betteridge, DR Illingworth, J. Shepherd. Arnold, London. 1999. pp. 1133–1144.

    Google Scholar 

  70. Walldius G, Wahlberg G. Nicotinic acid and its derivatives In Lipoproteins in Health and Disease. Editors DJ Betteridge, DR Illingworth, J Shepherd Arnold, London. 1999. pp. 1181–1198.

    Google Scholar 

  71. Leiter LA, Betteridge DJ, Chacra AR, et al. on behalf of the AUDIT Study Steering Committee. AUDIT study. Evidence of global undertreatment of dyslipidaemia in patients with type 2 diabetes. Br J Diabetes Vasc Dis. 2006;6:31–41.

    Article  Google Scholar 

  72. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet. 2005;366:1279–1288.

    Article  CAS  PubMed  Google Scholar 

  73. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes. JAMA. 2006;296:2572–2581.

    Article  CAS  PubMed  Google Scholar 

  74. Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized, controlled trial. Lancet. 2006 368;368:1660–1672.

    Article  CAS  PubMed  Google Scholar 

  75. Brown BG, Zhao X-Q, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med. 2001;345:1583–1592.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University College London Medical School, 5 University Street, WC1 6JJ, London, UK

    D. John Betteridge

Authors
  1. D. John Betteridge
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Aarhus University Hospital, Nørrebrogade 44, DK-8000, Aarhus, Denmark

    Carl Erik Mogensen MD

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Betteridge, D.J. (2007). Management of Diabetic Dyslipidaemia. In: Mogensen, C.E. (eds) Pharmacotherapy of Diabetes: New Developments. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-69737-6_16

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-69737-6_16

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-69736-9

  • Online ISBN: 978-0-387-69737-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation